Patents by Inventor Gediminas J. Brizgys
Gediminas J. Brizgys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250099431Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.Type: ApplicationFiled: September 19, 2024Publication date: March 27, 2025Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-yu Yang
-
Publication number: 20250084072Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: August 20, 2024Publication date: March 13, 2025Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
-
Publication number: 20250051375Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.Type: ApplicationFiled: May 29, 2024Publication date: February 13, 2025Inventors: Gediminas J. Brizgys, Michael O’ Neil Hanrahan Clarke, Raheel Fondekar, Bindu Goyal, Luisruben P. Martinez, Bradley Thomas Reid, Nathan D. Shapiro, Doris T. Tang
-
Patent number: 12180197Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: March 9, 2022Date of Patent: December 31, 2024Assignee: Gilead Sciences, Inc.Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, Scott D. Schroeder, Nathan D. Shapiro, Suzanne M. Szewczyk, James G. Taylor, Nathan E. Wright, Sheila M. Zipfel
-
Patent number: 12121511Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.Type: GrantFiled: January 27, 2021Date of Patent: October 22, 2024Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
-
Patent number: 12091404Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: March 9, 2022Date of Patent: September 17, 2024Assignee: Gilead Sciences, Inc.Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
-
Publication number: 20240199580Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: November 6, 2023Publication date: June 20, 2024Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
-
Patent number: 11851419Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: November 18, 2021Date of Patent: December 26, 2023Assignee: Gilead Sciences, Inc.Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
-
Publication number: 20230391747Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: May 10, 2023Publication date: December 7, 2023Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
-
Publication number: 20230257386Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.Type: ApplicationFiled: November 23, 2022Publication date: August 17, 2023Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas J. Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn S. Ndukwe, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
-
Patent number: 11702404Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: October 22, 2020Date of Patent: July 18, 2023Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
-
Publication number: 20230212148Abstract: Background: HIV capsid (CA) is an emerging target for antiretroviral treatment PF-3450074 (P74) is a small-molecule CA binder that has been proposed to inhibit reverse transcription (RT) by accelerating HIV core uncoating. PF74 antiviral potency can depend on cyclophilin A (CypA) binding to CA in some cells and it shares a CA binding site with the host nuclear transport factor CPSF6, which restrict HIV infection when mislocalized to the cell cytoplasm. Here we further interrogate the mechanism of action (MOA) for PF74 in human T cells and clarify its potential dependence on CypA and CPSF6. Methodology: HIV reporter viruses were produced in HEK293T cells and used to infect MT2 cells and primary CD4+ T cells to determine the antiviral effect of PF74. Compound exposure was controlled by staggered addition and cell washing at various times post-infection. DNA products of infection were analyzed by qPCR. CypA and CPSF6 levels were varied in MT2 cells by overexpression and shRNA knockdown.Type: ApplicationFiled: December 2, 2022Publication date: July 6, 2023Inventors: Gediminas J. Brizgys, Chienhung Chou, Hang Chu, Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B.C. Mack, Dong Min Mun, Scott D. Schroeder, William J. Watkins, Qiaoyin Wu, Jennifer R. Zhang
-
Publication number: 20230021705Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: April 19, 2022Publication date: January 26, 2023Inventors: Megan K. Armstrong, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Chao-I Hung, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
-
Publication number: 20220306614Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: March 9, 2022Publication date: September 29, 2022Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, Scott D. Schroeder, Nathan D. Shapiro, Suzanne M. Szewczyk, James G. Taylor, Nathan E. Wright, Sheila M. Zipfel
-
Publication number: 20220298148Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: March 9, 2022Publication date: September 22, 2022Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
-
Publication number: 20220288030Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.Type: ApplicationFiled: January 27, 2021Publication date: September 15, 2022Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
-
Publication number: 20220177449Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: November 18, 2021Publication date: June 9, 2022Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
-
Publication number: 20210171499Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: ApplicationFiled: October 22, 2020Publication date: June 10, 2021Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel